An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Psoriasis
Interventions
DRUG

VTP-43742

VTP-43742 administered as an oral capsule once daily

DRUG

Placebo 1

Placebo 1 matching VTP-43742 administered as an oral capsule once daily

DRUG

Placebo 2

Placebo 2 matching VTP-43742 administered as an oral capsule once daily

Trial Locations (14)

10012

Patient Site 2, New York

27265

Patient Site 9, High Point

33144

Patient Site 1, Miami

33609

Patient Site 8, Tampa

33624

Patient 12, Tampa

46032

Patient Site 13, Carmel

46168

Patient Site 4, Plainfield

72758

Patient Site 5, Rogers

75231

Patient Site 3, Dallas

77004

Patient Site 10, Houston

77065

Patient Site 11, Houston

77598

Patient Site 7, Webster

77845

Patient Site 6, College Station

07410

Healthy Volunteer Site 1, Fair Lawn

All Listed Sponsors
lead

Vitae Pharmaceuticals Inc., an Allergan affiliate

INDUSTRY

NCT02555709 - An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients | Biotech Hunter | Biotech Hunter